Zenas Biopharma, Inc. (ZBIO) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Zenas Biopharma, Inc., a Delaware corporation and emerging growth company, on August 12, 2026. The report covers events occurring on August 12, 2026, and references financial results for the quarter ended June 30, 2026, which were announced via press release on August 13, 2026.
Key Financial Metrics
The filing references the issuance of a press release (Exhibit 99.1) containing financial results for the quarter ended June 30, 2026. However, the text of this Form 8-K does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The filing explicitly states that the information in Item 2.02 and the associated exhibit is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Material Changes and Corporate Actions
- Board Appointment: The Board of Directors appointed Christy J. Oliger as a Class II director, effective September 1, 2026. Her term will last until the 2029 annual meeting of stockholders.
- Board Size: The authorized size of the Board was increased by one member effective September 1, 2026.
- Committee Assignments: Ms. Oliger will serve on the Nominating and Corporate Governance Committee and the Science and Technology Committee.
- Compensation: Ms. Oliger will receive an initial award of a non-qualified stock option to purchase 37,000 shares of common stock and cash compensation in accordance with the Company's Non-Employee Director Compensation Policy.
Guidance, Outlook, and Risks
The filing does not contain specific management commentary, forward-looking guidance, or a discussion of risks and contingencies beyond the standard legal disclaimers regarding the non-filing status of the financial results press release. No unusual items were disclosed in the text of this report.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 13, 2026) for specific Q2 2026 financial metrics, as they are not detailed in this 8-K text.
- Verify the independence status of the newly appointed director, Christy J. Oliger, under Nasdaq Global Select Market listing standards.
- Confirm the terms of the stock option grant (37,000 shares) and the effective date of September 1, 2026, in the Company's equity incentive plan records.
- Check the Company's Non-Employee Director Compensation Policy (filed as Exhibit 10.19 to the 2026 Form 10-K) for details on cash compensation rates.